Providence St. Joseph Health

Providence St. Joseph Health Digital Commons
Articles, Abstracts, and Reports
6-1-2019

Effect of Native Type I Collagen with Polyhexamethylene
Biguanide Antimicrobial on Wounds: Interim Registry Results.
Michael A Bain
Kerry T Thibodeaux
Marcus S Speyrer
Emily Carlson
George John Koullias

Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
Part of the Plastic Surgery Commons

Experimental
Effect of Native Type I Collagen with
Polyhexamethylene Biguanide Antimicrobial on
Wounds: Interim Registry Results
Michael A. Bain, MD, MMS*
Kerry T. Thibodeaux, MD,
FACS†
Marcus S. Speyrer, RN, CWS†
Emily Carlson, BA*
George John Koullias, MD, PhD‡

Background: Biofilm can impair wound healing by maintaining an elevated, but
ineffective, inflammatory state. This article describes interim results from the prospective RESPOND postmarketing registry evaluating the use of a native type 1,
porcine collagen matrix with the embedded antimicrobial polyhexamethylene biguanide (PCMP) in the management of chronic wounds.
Methods: Adults ≥18 years of age with ≥1 appropriate wound were eligible for inclusion. Data that were final on January 26, 2018 were included in this analysis. At
week 0, wounds were cleaned, debrided, and prepared as necessary and PCMP was
applied, with a dressing to fix it in place. Patients received standard wound care
plus PCMP weekly, up to 24 weeks, at the investigator’s discretion. At each visit,
wounds were assessed for area and quality of granulation tissue.
Results: Most common wound types (N = 63) were venous ulcers (28.6%), trauma
and lacerations (22.2%), postsurgical open wounds (15.9%), pressure injuries
(12.7%), and diabetic ulcers (9.5%). Median baseline wound area was 6.5 cm2;
mean wound duration at baseline was 4 months. Of the 63 wounds, 43 (68.3%)
achieved complete wound closure, 41 of 43 (95.3%) closed after PCMP treatment,
and 2 of 43 (4.7%) after bridging to other modalities and surgical closure. Twelve
out of 63 wounds were bridged to other modalities after PCMP treatment. Mean
time to closure for PCMP wounds was 5.0 weeks.
Conclusions: PCMP appears to be a useful adjunct for treating various wound
types. PCMP use should be considered when managing chronic or acute wounds.
(Plast Reconstr Surg Glob Open 2019;7:e2251; doi: 10.1097/GOX.0000000000002251;
Published online 12 June 2019.)

INTRODUCTION

All wounds progress through a series of predictable
stages before achieving complete wound closure.1 However, some wounds stall in the healing process and become
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chronic.2 The etiology of chronic nonhealing wounds is
complex, but many occur as a result of increased bacterial
bioburden and the formation of biofilm.3,4 Biofilm represents a stage of the normal growth cycle of bacteria, during which they are in a protected state.
A recent meta-analysis calculated the prevalence of
biofilms in chronic wounds at 78.2%, and in some studies, the rates are even higher.5–9 Elevated bioburden and
biofilm can also be found in acute wounds, such as burns
and skin tears with tissue loss, with biofilm present in approximately 6% of acute wounds.8,10,11
Biofilm can impair wound healing by producing an elevated, but ineffective, inflammatory state.12 The formation
of a biofilm results in an increase in proteolytic enzymes
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that manipulate the host response by inducing proinflammatory cytokines and proteases.13 This creates a cascade of
changes that induce chronic inflammation and turn acute
wounds into chronic wounds. Because of the extracellular
polymeric substance secreted by the bacterial species in a
biofilm, neutrophils and macrophages are unable to penetrate the biofilm and are rendered ineffective.
Debridement is an essential step in disrupting biofilm,
but it is not sufficient by itself to reduce and maintain lower bacterial counts in wounds.14–16 A reduction in bacterial counts for up to 48 hours after debridement has been
noted.17 After debridement, the use of topical antimicrobials is a treatment strategy that can be effective in reducing
and maintaining lower bacterial counts and preventing
biofilm reformation.18,19
Polyhexamethylene biguanide (PHMB) is a cationic
topical antimicrobial that strongly binds to bacterial
cell walls and membranes, disrupting the transport,
biosynthesis, and catabolic functions of the bacteria.20,21 PHMB possesses broad antimicrobial activity
against gram-positive and gram-negative bacteria, and
plaque- and biofilm-forming bacteria.21 Furthermore,
PHMB binds to biofilm matrix components, and the
local PHMB concentration increases during application to cause an increasingly toxic environment for
the bacteria.22 Multidrug efflux pumps or acquired resistance to an antimicrobial compound developed by
the bacteria do not appear to affect PHMB efficacy.20,21
PHMB shows good biocompatibility and little to no toxicity or systemic uptake when applied on intact skin or
wounds.21,23 PHMB also shows activity against a variety
of other microorganisms including yeast and fungi.24,25
PHMB has been effective in wound care of leg ulcers
and prevention of central-line–associated bloodstream
infections.26,27
Collagen dressings are frequently used in wound care,
owing to their properties that encourage cellular migration and new tissue formation, and to their ease of handling and conformability.28,29 Matrices made of native
collagen can be beneficial in promoting wound healing.28
The native collagen matrix possesses many properties that
make it attractive for wound management. The network
provides a scaffold for constructive tissue remodeling, allowing fibroblasts and keratinocytes to attach, proliferate,
and migrate.30,31 Native collagen matrices possess strength
and flexibility, as well as growth factors that are released
during matrix degradation.31,32 Another role that collagen
matrices play is to act as a substrate to decrease the high
levels of elastase and matrix metalloproteinases that are
often present in chronic wounds.29,33
A recent development in wound healing is a skin substitute construct of a native type 1, porcine-derived collagen matrix with a 0.1% PHMB coating (porcine collagen
matrix with PHMB, further referenced as PCMP). PCMP
is a US Food and Drug Administration Class II medical device, 510(k)-cleared #K051647, and intended for the management of wounds. PCMP is supplied dry in sheet form
and packaged as sterile, sealed single patches.34
PCMP is a native extracellular matrix (ECM) made
from small intestine submucosa (SIS) that retains the na-

2

tive structure of collagen, with the addition of PHMB. SIS
grafts provide structure for vascular and cellular ingrowth.
Grafts with intact collagen structure are more resistant to
enzymatic degradation and obtain better cell adhesion
compared with those made from denatured collagen. The
addition of PHMB to the SIS graft (or native ECM) provides all of the above attributes and antimicrobial action
against a broad spectrum of bacteria.
The RESPOND Registry (Real-World Effectiveness
Study of PuraPly AM on Wounds) is a postmarketing,
open-label, prospective, observational multicenter study
(ClinicalTrials.gov Registration #NCT03286452; registered September 18, 2017) examining the use of PCMP in
treating wounds in real-world clinical settings. The aim of
this study is to determine the impact of PCMP on wound
environment and management of chronic wounds (eg,
increase in healthy granulation tissue, decrease in bioburden, and decrease in amount of exudate) for up to 24
weeks.
This article reports an interim analysis of 63 patients
in the RESPOND registry treated with PCMP (PuraPly Antimicrobial, Organogenesis Inc., Canton, Mass.) who had
completed their participation and whose data were final as
of January 26, 2018. Over 300 patients are enrolled in the
registry to date.

METHODS

The registry protocol was reviewed and approved by
Sterling Institutional Review Board (registration number IRB00001790) and was conducted in accordance
with current International Council for Harmonisation
Good Clinical Practice guidelines and 21 CFR Parts 11,
50, 56, and applicable regulations. All patients provided their written informed consent to participate in the
registry.
One target wound per patient was identified for study
inclusion and was followed for up to 24 weeks. The choice
to initiate treatment of the wound with PCMP was made by
the Investigator, independent of and before the patient’s
decision to participate in the RESPOND registry. Patients
received standard wound treatment and clinical assessments appropriate for their wound type, as determined by
the Investigator.
Patients

Adults ≥18 years of age with at least 1 appropriate
wound (partial and full-thickness wounds of various etiologies including pressure injuries, venous ulcers, diabetic
ulcers, chronic vascular ulcers, open surgical wounds, or
trauma wounds with tissue loss) were eligible for inclusion. The term “pressure injury” is interchangeable with
“pressure ulcer” and describes localized damage to the
skin and underlying soft tissue, usually over a bony prominence or related to a medical or other device. Individuals
were excluded from participating if they were receiving
concurrent treatment with other topical antimicrobials
or skin substitute products, if they had received previous PCMP treatment for the study wound, or if they had
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a third-degree burn or a known sensitivity to any of the
PCMP materials.
The primary objective was to assess the effectiveness of
PCMP in real-world clinical settings, as measured by percent reduction in wound area, time to complete wound
closure, and improvement in wound bed condition (as
indicated by an increase in healthy granulation tissue, reduction in biofilm, reduction in amount of exudate, and
readiness for application of advanced therapy).

assessment within the first week of enrollment. Patients
with venous ulcers received endovenous procedures to
correct venous insufficiency, and patients with arterial
insufficiency received arterial interventions to augment
wound healing, all within the first 2 weeks of entering
the study. The use of vascular intervention in patients
with venous or arterial insufficiency at enrollment is in
concordance with clinical practice guidelines for the
management of peripheral artery disease.35,36 In these patients, and all others in this study, PCMP was used as an
adjunct to standard of care.

Procedures

Assessments

Objectives

Eligible and enrolled patients received their initial
PCMP application at the baseline visit. Baseline assessments included patient demographics, medical and
surgical history, target wound etiology, duration and recurrence information, and previous surgical interventions
and treatments (ie, offloading, compression, skin substitutes, hyperbaric oxygen, and negative pressure wound
therapy).
Before the first application, the target wound was
cleansed, debrided as necessary, and measurements (surface area and depth) were taken. PCMP was applied and
the patient returned to the clinic weekly for subsequent
PCMP applications and wound care assessments. The investigator determined the frequency and type of assessments and standard wound care for each patient, but the
clear majority of patients received a weekly wound surgical
and/or sharp debridement, followed by wound brushing,
cleansing with normal saline, and PCMP reapplication.
Data were collected at each patient visit during which
PCMP was applied, and at postapplication follow-up visits
as appropriate for up to 24 weeks.
The registry protocol did not specify how the investigator was to perform normal wound care using PCMP. An
example of a typical regimen at 2 of the study sites is as
follows: Wounds were cleansed and debrided at the initial
visit. After initial debridement, cultures would be taken
if the patient’s wound was boggy, purulent, or cellulitic.
PCMP was applied unless gross purulence was noted. After
wound bed preparation, PCMP was applied, wetted with
normal saline, affixed with Steri-Strips, and subsequently
hydrogel and a nonstick layer were applied. Each PCMP
sheet could remain on the study wound for 1 week. Dressings applied over PCMP were left to the treating physician;
for example, a hydrogel and a low evaporative dressing
(Adaptic or Xeroform) were often applied over PCMP. Patients would be placed in compression wraps if indicated
(eg, in cases of venous leg ulcers). PCMP would then be
reapplied weekly. After 4–6 weeks, the decision was made
to switch to a cellular graft if there was no significant reduction in wound/ulcer size, or to continue with PCMP if
the wound was reducing in size.
At one of the authors’ institutions, patients entering
the study with lower extremity wounds and lower extremity edema received a venous duplex assessment for
venous insufficiency and reflux, and all patients entering the study with lower extremity wounds with nonpalpable pulses had, at minimum, an ankle-brachial index

At each follow-up clinic visit, wound characteristics,
size (area and depth), and quality of granulation tissue
were assessed and recorded. PCMP was applied weekly at
the investigator’s discretion, and photographs were taken
of the wound before and after PCMP application and debridement, if performed, and upon healing, if it occurred.
Any pertinent concomitant treatments, procedures,
and medications, and target wound-related adverse events
were assessed and recorded.
Statistical Analysis

Data from patients who received PCMP and completed
the study by the interim analysis cutoff date (January 26,
2018) were analyzed. Descriptive statistics (mean, SD) and
percentage wound closure at 4, 8, and 12 weeks and at
the end of study were calculated with Microsoft Excel 2016
(version 16.0.9330.2124).

RESULTS

A total of 63 patients completed the study by the data
cutoff. The mean (SD) age of patients was 76.1 (13.8)
years and 32 (50.8%) were male (Table 1). At baseline,
18 of 63 (28.6%) of wounds were venous ulcers, 14 of 63
(22.2%) were trauma and lacerations (category includes
skin tears [n = 2], and wound dehiscence [n = 1] 10 of 63
(15.9%) were postsurgical open wounds, 8 of 63 (12.7%)
were pressure injuries, 6 of 63 (9.5%) were diabetic ulcers, 2 of 63 (3.2%) were chronic vascular wounds, and
5 of 63 (7.9%) were another type, including tick bite
(n = 1) and vasculitis (n = 1) (data were unavailable for
the 3 remaining wounds marked as “other”). The median (interquartile range) baseline wound area was 6.5
(11.8) cm2. The mean baseline wound duration was 4
months. The 63 wounds in this interim analysis received
an average of 4 PCMP applications each. Some patients
received adjunct therapy during their registry participation.
Of the 63 wounds, 43 (68.3%) achieved complete
wound closure by the interim analysis cutoff date (Fig. 1).
Of the 43 wounds that achieved complete wound closure,
41 of 43 (95.3%) closed after PCMP treatment and 2 of
43 (4.7%) after bridging to other modalities and surgical
closure. Overall, 12 of 63 wounds were bridged to other
modalities after PCMP treatment. Two examples of wound
healing are shown in Figure 3.
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Table 1. Demographic and Baseline Characteristics
Interim Analysis Group
(N = 63)

Characteristic
Mean age, y (SD)
Sex, n (%)
 Female
 Male
Race, n (%)
 White
 Black
 Hispanic
 Unknown
BMI, kg/m2, mean (SD)a
Wound type, n (%)
 Venous ulcer
 Trauma and laceration
 Postsurgical wound
 Pressure injury
 Diabetic ulcer
 Chronic vascular wound
 Other

76.1 (13.8)
31 (49.2)
32 (50.8)
51 (81.0)
8 (12.7)
2 (3.2)
2 (3.2)
26.6 (6.6)a
18 (28.6)
14 (22.2)
10 (15.9)
8 (12.7)
6 (9.5)
2 (3.2)
5 (7.9)

a
n = 51.
BMI, body mass index.

At week 4, 33.3% (21 of 63) of wounds had completely healed, and at week 8, 50.8% had completely healed.
Wound closure by wound type at Weeks 4, 8, and 12 is
shown in Figure 2. The mean and median time to wound
closure was 5.0 weeks for those that closed after PCMP
treatment. In the wounds that did not achieve complete
closure, 14 decreased in area from baseline to the end
of the study by an average of 54.1%, and 5 increased in
size (data on the lesion area at the end of the study timepoint were missing for 1 patient). The 2 chronic vascular
wounds did not heal. The 5 patients who had enlarged
wounds ranged in age from 69 to 91 years, and the wounds
had been present for 1–4 months (wound duration was
unavailable for 1 of these 5 patients). The 5 wounds that
increased in size were venous ulcers (n = 2), pressure ul-

cer (n = 1), postsurgery (n = 1), and post-Moh’s surgery
(n = 1). Reasons or other factors given for increase in
wound size were: congestive heart failure, renal failure,
and chronic obstructive pulmonary disease led to death
within 3 weeks (venous ulcer); worsening infection with
contributing factors of polymyalgia rheumatica (treated
with low-dose prednisone) and thrombocytosis (treated
with hydroxyurea) (venous ulcer); myocardial infarction,
peripheral vascular disease, and bladder cancer resulted
in transfer to hospice 2 weeks into the study (postsurgical wound); after 4 weeks of treatment, patient dropped
out of registry and transferred to different facility (postMoh’s surgery), and noncompliance (pressure ulcer).
There were 2 deaths during the study (1 due to natural
causes; 1 due to exacerbations of chronic obstructive pulmonary disease). There were 5 registry discontinuations
before healing or before reaching the end of the study
(2 transfer to hospice; 1 Investigator decision; 2 lost to
follow-up).
Two adverse events of worsening infection and worsening of wound appearance were reported during the
study, both of which were mild and were not attributed to
PCMP. The patient reporting a worsening infection had
swabs of the venous leg ulcer that were sent for culture,
which returned positive. The patient was started on antibiotics and this event was reported as worsening infection. This patient also showed wound enlargement. The
patient reporting worsening wound appearance had a
diabetic foot ulcer that had been present for many years,
which had healed a few times but continued to reopen.
The wound was reported as showing a decline during this
registry enrollment, which was reported as worsening in
appearance.

Fig. 1. Complete wound closure after PCMP treatment at week 12, by baseline wound type.
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Fig. 2. Healing trajectory of various wound types. Wound closure rates over time show an increase in the
percentage of wounds achieving closure from the beginning of the study through Week 12. All wound
types, except for chronic vascular wounds, exhibited some wound closure throughout the study.

DISCUSSION

Results of the interim analysis of the RESPOND Registry
show that PCMP appeared to positively impact wound healing in a variety of lesion types. Many wounds (68%) achieved
complete closure by 12 weeks, and most (90%) had reduced
in area from baseline. Complete wound closure was achieved
in an average of 5 weeks, which was less than the mean duration of the wounds (12 weeks) before PCMP treatment.
Complete wound closure was seen in many wound
types, including trauma wounds and lacerations with tissue loss, venous ulcers, postsurgical wounds, and pressure
injuries. Of the wounds that did not achieve complete
closure in the study period, 2 were chronic vascular ulcers, which lack vascularity and tend not to heal regardless of treatment modality. PCMP was well tolerated, and
no treatment-related adverse events were reported in this
study. Results seen here were similar to an earlier case series of PCMP in chronic wounds of various etiology.37
The wound closure results may be attributed to the
synergistic effect of the native collagen matrix, which provides a structural substrate and environmental conditions
that support tissue ingrowth and reduce protease activity, and the PHMB antimicrobial, which inhibits bacterial
growth. The collagen matrix by itself does not appear to
possess antimicrobial properties.38
In this study, patients did not show any hypersensitivity to PCMP components, and the PHMB antimicrobial
is known to be very biocompatible. PCMP was also used
in conjunction with other treatments during this study,

including oral and intravenous antibiotic therapy, and
hyperbaric oxygen, with no detectable interactions or adverse effects.
As described by the authors representing a study site
contributing to this interim data set, the use of PCMP had
a positive influence on the healthcare costs associated
with treating patients with appropriate wounds. With a
streamlined application process for PCMP and the rates
of healing and time to healing seen in the patients treated
with PCMP, the medical center considered it a beneficial
management plan.
PCMP was not compared with another treatment or to
a standard-of-care group in this study, and the final results
from the full registry enrollment of more than 300 patients may provide a broader perspective on the outcomes
following the use of PCMP. In all patients enrolled in this
registry, PCMP was used as an adjunct to standard of care.
Wounds represented in this study were likely to be those
that were amenable to healing without surgery (eg, ulcers
that were stage 3 or less), and PCMP was useful to aid healing with these wounds. Skin substitutes, including PCMP,
are intended to keep patients out of the operating room
as much as possible and heal as many as possible without
the need for surgery.
PCMP may be useful for wound management owing
to its combination of native ECM and PHMB, ease of application, long shelf life, and the range of sizes available
for managing different wound types. The success of the
wound management strategy seen here demonstrates the
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Fig. 3. A, A 58-year-old female presented with a large arterial ischemic ulcer to her lower extremity, which had been present for 56 days
prior to PCMP application. She received treatments including surgical debridement, 40 hyperbaric oxygen therapy treatments, negative
pressure therapy, and 10 PCMP applications. The clinician’s goal of therapy was to progress the wound to be ready for a split-thickness
skin graft. The patient was offered a split-thickness skin graft at week 24 but chose not to undergo grafting due to personal reasons, so
she preferred to continue the existing course of treatment.
B, Wound at Week 6
C, At week 52 the patient was discharged with 95% epithelialization. The wound was completely healed at 22 months after initial presentation at the wound center.
D, A 55-year-old female presented with a history of a traumatic wound, which had been present for 1 week. She received surgical debridement and 4 PCMP applications.
E, Wound at Week 14.
F, Wound was completely healed at 28 weeks after PCMP applications began.

importance of addressing bioburden, biofilm reformation,
and high proteolytic activity to improve wound outcomes.

CONCLUSIONS
PCMP appears to be a useful adjunct in the treatment
of various types of wounds. Its action against biofilm warrants further evaluation. It seems that the combined action

6

of the PCMP components, native collagen matrix with addition of PHMB, may result in a faster time to wound closure than either component could achieve individually. In
this case, the use of PCMP was associated with substantial
reduction in wound area after 4 weeks and notable rates
of wound closure at up to 12 weeks. PCMP use should be
considered when managing chronic or acute wounds of
various etiologies. We will await final data to determine if
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further study is needed to compare PCMP to other products on the outcomes measured.
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